Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Alzheimer Disease | 44 | 2023 | 2118 | 4.910 |
Why?
|
Brain | 41 | 2023 | 1663 | 4.780 |
Why?
|
Dementia | 20 | 2022 | 573 | 3.720 |
Why?
|
Cognition Disorders | 28 | 2020 | 1003 | 3.640 |
Why?
|
Diabetes Mellitus | 10 | 2023 | 137 | 3.540 |
Why?
|
Diabetes Mellitus, Type 2 | 9 | 2020 | 191 | 2.800 |
Why?
|
Cognition | 18 | 2024 | 1352 | 2.350 |
Why?
|
Aged, 80 and over | 60 | 2022 | 4851 | 2.060 |
Why?
|
Brain Infarction | 7 | 2021 | 75 | 2.050 |
Why?
|
Insulin | 7 | 2023 | 90 | 1.990 |
Why?
|
Cognitive Dysfunction | 9 | 2024 | 1065 | 1.920 |
Why?
|
Insulin Resistance | 4 | 2023 | 52 | 1.780 |
Why?
|
Cerebral Infarction | 7 | 2023 | 148 | 1.750 |
Why?
|
Cerebrovascular Disorders | 4 | 2021 | 134 | 1.660 |
Why?
|
Neuropsychological Tests | 32 | 2024 | 1226 | 1.630 |
Why?
|
Aging | 23 | 2022 | 1549 | 1.630 |
Why?
|
Humans | 98 | 2024 | 28395 | 1.580 |
Why?
|
Antibodies, Antiphospholipid | 3 | 2019 | 23 | 1.510 |
Why?
|
Neurofibrillary Tangles | 7 | 2018 | 193 | 1.490 |
Why?
|
Aged | 59 | 2024 | 9256 | 1.480 |
Why?
|
tau Proteins | 9 | 2021 | 235 | 1.460 |
Why?
|
Blood Pressure | 5 | 2020 | 207 | 1.430 |
Why?
|
Female | 73 | 2024 | 15704 | 1.390 |
Why?
|
Male | 71 | 2022 | 15269 | 1.330 |
Why?
|
Risk Factors | 23 | 2024 | 2408 | 1.160 |
Why?
|
Memory Disorders | 5 | 2020 | 162 | 1.100 |
Why?
|
Biomarkers | 5 | 2024 | 596 | 1.070 |
Why?
|
Plaque, Amyloid | 6 | 2018 | 146 | 1.040 |
Why?
|
Cohort Studies | 21 | 2022 | 1926 | 1.030 |
Why?
|
Cardiovascular Diseases | 4 | 2024 | 372 | 1.020 |
Why?
|
Apolipoprotein E4 | 9 | 2022 | 264 | 0.960 |
Why?
|
Amyloid beta-Peptides | 5 | 2021 | 327 | 0.960 |
Why?
|
Insulin-Like Growth Factor I | 2 | 2024 | 59 | 0.940 |
Why?
|
Longitudinal Studies | 23 | 2020 | 1384 | 0.930 |
Why?
|
Memory, Episodic | 2 | 2023 | 116 | 0.910 |
Why?
|
Signal Transduction | 4 | 2021 | 447 | 0.870 |
Why?
|
Metformin | 1 | 2023 | 20 | 0.860 |
Why?
|
Neuroimaging | 4 | 2021 | 128 | 0.830 |
Why?
|
Cell-Free Nucleic Acids | 1 | 2023 | 13 | 0.820 |
Why?
|
Radar | 1 | 2022 | 6 | 0.790 |
Why?
|
Cerebral Amyloid Angiopathy | 6 | 2021 | 113 | 0.790 |
Why?
|
Diabetes Complications | 6 | 2021 | 59 | 0.750 |
Why?
|
Cross-Sectional Studies | 8 | 2024 | 932 | 0.720 |
Why?
|
Neuropathology | 2 | 2019 | 82 | 0.720 |
Why?
|
Hypoglycemic Agents | 3 | 2019 | 40 | 0.710 |
Why?
|
White Matter | 4 | 2019 | 134 | 0.700 |
Why?
|
Body Mass Index | 3 | 2020 | 465 | 0.690 |
Why?
|
Autopsy | 9 | 2021 | 343 | 0.690 |
Why?
|
Hypertension | 2 | 2020 | 244 | 0.660 |
Why?
|
Adipokines | 1 | 2019 | 7 | 0.660 |
Why?
|
Drug Repositioning | 1 | 2019 | 5 | 0.660 |
Why?
|
Cerebral Arteries | 3 | 2016 | 25 | 0.650 |
Why?
|
Motor Disorders | 1 | 2019 | 23 | 0.630 |
Why?
|
Insulin-Like Growth Factor Binding Protein 5 | 1 | 2019 | 26 | 0.630 |
Why?
|
Parkinsonian Disorders | 5 | 2010 | 226 | 0.600 |
Why?
|
Geriatric Assessment | 3 | 2016 | 211 | 0.580 |
Why?
|
Depressive Disorder | 1 | 2019 | 185 | 0.580 |
Why?
|
Gray Matter | 2 | 2015 | 51 | 0.580 |
Why?
|
Follow-Up Studies | 9 | 2020 | 1858 | 0.510 |
Why?
|
Heme Oxygenase-1 | 3 | 2014 | 7 | 0.440 |
Why?
|
5-Methylcytosine | 2 | 2023 | 6 | 0.430 |
Why?
|
Intracranial Arteriosclerosis | 3 | 2021 | 53 | 0.410 |
Why?
|
Epidemiologic Research Design | 1 | 2012 | 15 | 0.410 |
Why?
|
Hypercholesterolemia | 2 | 2010 | 27 | 0.410 |
Why?
|
Movement Disorders | 1 | 2012 | 90 | 0.380 |
Why?
|
Mental Status Schedule | 5 | 2018 | 93 | 0.370 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2010 | 61 | 0.360 |
Why?
|
Heptanoic Acids | 1 | 2010 | 5 | 0.340 |
Why?
|
Middle Aged | 18 | 2024 | 9250 | 0.340 |
Why?
|
Age Factors | 5 | 2021 | 781 | 0.340 |
Why?
|
Pyrroles | 1 | 2010 | 24 | 0.340 |
Why?
|
Frontotemporal Dementia | 1 | 2010 | 13 | 0.340 |
Why?
|
Vascular Diseases | 2 | 2021 | 44 | 0.330 |
Why?
|
Memory | 5 | 2020 | 302 | 0.330 |
Why?
|
Neurodegenerative Diseases | 2 | 2001 | 124 | 0.330 |
Why?
|
Prospective Studies | 7 | 2020 | 1804 | 0.320 |
Why?
|
Cerebral Cortex | 4 | 2022 | 161 | 0.320 |
Why?
|
Apolipoproteins E | 5 | 2022 | 252 | 0.320 |
Why?
|
Phospholipases A2, Cytosolic | 3 | 2022 | 6 | 0.290 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2008 | 111 | 0.280 |
Why?
|
Risk Assessment | 4 | 2022 | 676 | 0.280 |
Why?
|
Asparagine | 1 | 2006 | 2 | 0.280 |
Why?
|
Smoking | 3 | 2020 | 176 | 0.280 |
Why?
|
Linear Models | 3 | 2020 | 251 | 0.280 |
Why?
|
Lysine | 1 | 2006 | 15 | 0.280 |
Why?
|
Logistic Models | 5 | 2017 | 395 | 0.270 |
Why?
|
Gait Disorders, Neurologic | 2 | 2007 | 138 | 0.270 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2024 | 71 | 0.260 |
Why?
|
Incidence | 5 | 2020 | 773 | 0.260 |
Why?
|
Neuroglia | 2 | 2007 | 49 | 0.260 |
Why?
|
Magnetic Resonance Imaging | 6 | 2015 | 1143 | 0.240 |
Why?
|
Independent Living | 2 | 2018 | 318 | 0.240 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2005 | 34 | 0.240 |
Why?
|
Postmortem Changes | 3 | 2019 | 31 | 0.240 |
Why?
|
Hospitalization | 2 | 2018 | 323 | 0.240 |
Why?
|
Mutation | 1 | 2006 | 353 | 0.240 |
Why?
|
Lewy Body Disease | 4 | 2012 | 100 | 0.240 |
Why?
|
Diabetic Neuropathies | 1 | 2004 | 12 | 0.240 |
Why?
|
Animals | 7 | 2022 | 3780 | 0.240 |
Why?
|
Calcium | 3 | 2022 | 381 | 0.230 |
Why?
|
Brain-Derived Neurotrophic Factor | 1 | 2024 | 48 | 0.220 |
Why?
|
Neurons | 3 | 2022 | 342 | 0.220 |
Why?
|
Insulin Receptor Substrate Proteins | 2 | 2014 | 15 | 0.210 |
Why?
|
Biomedical Research | 1 | 2023 | 66 | 0.200 |
Why?
|
Group IV Phospholipases A2 | 1 | 2022 | 6 | 0.200 |
Why?
|
Creatinine | 1 | 2002 | 53 | 0.200 |
Why?
|
Anniversaries and Special Events | 1 | 2021 | 3 | 0.200 |
Why?
|
Inflammation | 3 | 2022 | 284 | 0.190 |
Why?
|
Neuromuscular Diseases | 1 | 2001 | 5 | 0.190 |
Why?
|
Hemoglobins | 1 | 2022 | 78 | 0.190 |
Why?
|
DNA Methylation | 1 | 2023 | 165 | 0.180 |
Why?
|
Amyloid beta-Protein Precursor | 1 | 2021 | 17 | 0.180 |
Why?
|
MAP Kinase Signaling System | 1 | 2021 | 37 | 0.180 |
Why?
|
Genetic Variation | 2 | 2016 | 97 | 0.180 |
Why?
|
Child, Preschool | 1 | 2022 | 689 | 0.170 |
Why?
|
Excitatory Amino Acid Antagonists | 1 | 2019 | 15 | 0.170 |
Why?
|
Memantine | 1 | 2019 | 9 | 0.170 |
Why?
|
Cholinesterase Inhibitors | 1 | 2019 | 15 | 0.170 |
Why?
|
Cerebrovascular Circulation | 2 | 2019 | 34 | 0.170 |
Why?
|
Leptin | 1 | 2019 | 22 | 0.160 |
Why?
|
Mental Status and Dementia Tests | 1 | 2019 | 69 | 0.160 |
Why?
|
Metabolic Syndrome | 1 | 2020 | 62 | 0.160 |
Why?
|
Blood Pressure Determination | 1 | 2019 | 16 | 0.160 |
Why?
|
HSP27 Heat-Shock Proteins | 1 | 2019 | 18 | 0.160 |
Why?
|
Arteriolosclerosis | 2 | 2018 | 77 | 0.160 |
Why?
|
Comorbidity | 4 | 2014 | 500 | 0.150 |
Why?
|
Frontal Lobe | 1 | 1999 | 81 | 0.150 |
Why?
|
Blood Glucose | 1 | 2019 | 108 | 0.150 |
Why?
|
Temporal Lobe | 1 | 1999 | 84 | 0.150 |
Why?
|
Central Nervous System Infections | 1 | 1998 | 4 | 0.150 |
Why?
|
Mycobacterium tuberculosis | 1 | 1998 | 17 | 0.150 |
Why?
|
Economics | 1 | 2018 | 17 | 0.150 |
Why?
|
Community Health Planning | 1 | 2018 | 21 | 0.150 |
Why?
|
Proteomics | 1 | 2019 | 93 | 0.150 |
Why?
|
Tuberculosis | 1 | 1998 | 20 | 0.150 |
Why?
|
Brain Diseases | 1 | 1999 | 67 | 0.150 |
Why?
|
Mice | 5 | 2022 | 1461 | 0.150 |
Why?
|
Mice, Transgenic | 4 | 2022 | 225 | 0.140 |
Why?
|
Prefrontal Cortex | 1 | 2019 | 137 | 0.140 |
Why?
|
Sex Characteristics | 1 | 2018 | 118 | 0.140 |
Why?
|
Astrocytes | 2 | 2021 | 150 | 0.140 |
Why?
|
Lewy Bodies | 3 | 2015 | 194 | 0.140 |
Why?
|
Ambulatory Care | 1 | 2017 | 74 | 0.140 |
Why?
|
Health Literacy | 1 | 2018 | 108 | 0.130 |
Why?
|
Religious Personnel | 1 | 2016 | 11 | 0.130 |
Why?
|
PubMed | 1 | 2016 | 10 | 0.130 |
Why?
|
Arterioles | 1 | 2016 | 12 | 0.130 |
Why?
|
Organ Specificity | 1 | 2016 | 42 | 0.130 |
Why?
|
Nerve Degeneration | 2 | 2014 | 49 | 0.130 |
Why?
|
Depression | 1 | 2020 | 452 | 0.130 |
Why?
|
Reactive Oxygen Species | 3 | 2022 | 119 | 0.120 |
Why?
|
Chromosomes, Human, Pair 17 | 2 | 2006 | 7 | 0.120 |
Why?
|
Chronic Disease | 1 | 2017 | 441 | 0.120 |
Why?
|
Diagnosis, Differential | 2 | 2010 | 372 | 0.120 |
Why?
|
beta 2-Glycoprotein I | 1 | 2014 | 7 | 0.120 |
Why?
|
Phosphatidylserines | 1 | 2014 | 7 | 0.120 |
Why?
|
Lupus Coagulation Inhibitor | 1 | 2014 | 7 | 0.120 |
Why?
|
Motor Skills | 1 | 2015 | 52 | 0.120 |
Why?
|
Autoantigens | 1 | 2014 | 25 | 0.120 |
Why?
|
Serine | 1 | 2014 | 11 | 0.120 |
Why?
|
Microglia | 1 | 2016 | 145 | 0.120 |
Why?
|
Residence Characteristics | 1 | 2016 | 214 | 0.120 |
Why?
|
Single-Blind Method | 1 | 2014 | 110 | 0.120 |
Why?
|
Tauopathies | 1 | 2014 | 21 | 0.120 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2020 | 329 | 0.110 |
Why?
|
Inclusion Bodies | 1 | 2014 | 13 | 0.110 |
Why?
|
Neoplasms | 1 | 2017 | 239 | 0.110 |
Why?
|
Membrane Proteins | 1 | 2014 | 171 | 0.100 |
Why?
|
Atrophy | 3 | 2005 | 93 | 0.100 |
Why?
|
Supranuclear Palsy, Progressive | 2 | 2003 | 28 | 0.100 |
Why?
|
Hallucinations | 1 | 2012 | 64 | 0.100 |
Why?
|
Immunohistochemistry | 2 | 2021 | 362 | 0.100 |
Why?
|
Motor Activity | 1 | 2015 | 329 | 0.100 |
Why?
|
Phosphorylation | 3 | 2021 | 149 | 0.100 |
Why?
|
Leukotriene B4 | 2 | 2022 | 5 | 0.100 |
Why?
|
Synaptosomes | 2 | 2022 | 8 | 0.100 |
Why?
|
Apolipoprotein E3 | 2 | 2022 | 16 | 0.100 |
Why?
|
Peptide Fragments | 2 | 2021 | 77 | 0.090 |
Why?
|
Statistics as Topic | 3 | 2007 | 107 | 0.090 |
Why?
|
United States | 6 | 2020 | 2196 | 0.090 |
Why?
|
Disease Progression | 3 | 2016 | 717 | 0.090 |
Why?
|
Oxidative Stress | 2 | 2022 | 107 | 0.090 |
Why?
|
Severity of Illness Index | 2 | 2015 | 985 | 0.090 |
Why?
|
Microcirculation | 1 | 2011 | 29 | 0.090 |
Why?
|
Chicago | 3 | 2020 | 939 | 0.090 |
Why?
|
Heterozygote | 3 | 2021 | 102 | 0.090 |
Why?
|
Research Design | 1 | 2012 | 207 | 0.090 |
Why?
|
Amyloid | 1 | 2010 | 56 | 0.090 |
Why?
|
Hippocampus | 3 | 2022 | 278 | 0.090 |
Why?
|
Adult | 5 | 2020 | 8097 | 0.090 |
Why?
|
Dementia, Vascular | 2 | 2007 | 45 | 0.090 |
Why?
|
Clergy | 3 | 2006 | 92 | 0.090 |
Why?
|
Terminology as Topic | 1 | 2010 | 32 | 0.080 |
Why?
|
Sterols | 1 | 2009 | 5 | 0.080 |
Why?
|
Family Health | 2 | 2006 | 36 | 0.080 |
Why?
|
Public Health | 1 | 2010 | 68 | 0.080 |
Why?
|
Postural Balance | 2 | 2007 | 122 | 0.080 |
Why?
|
Glial Fibrillary Acidic Protein | 2 | 2007 | 42 | 0.080 |
Why?
|
Regression Analysis | 3 | 2021 | 266 | 0.080 |
Why?
|
Accidental Falls | 1 | 2010 | 113 | 0.080 |
Why?
|
Intracranial Hemorrhages | 1 | 2008 | 13 | 0.070 |
Why?
|
Isometric Contraction | 1 | 2007 | 13 | 0.070 |
Why?
|
Housing for the Elderly | 1 | 2007 | 8 | 0.070 |
Why?
|
Receptors, Erythropoietin | 1 | 2007 | 2 | 0.070 |
Why?
|
Protein Processing, Post-Translational | 2 | 2021 | 39 | 0.070 |
Why?
|
Neuroprotective Agents | 1 | 2008 | 55 | 0.070 |
Why?
|
Lower Extremity | 1 | 2007 | 39 | 0.070 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2006 | 37 | 0.070 |
Why?
|
Positron-Emission Tomography | 1 | 2006 | 89 | 0.070 |
Why?
|
Decision Support Techniques | 1 | 2006 | 52 | 0.070 |
Why?
|
Parkinson Disease | 3 | 2005 | 844 | 0.070 |
Why?
|
Gait | 2 | 2007 | 412 | 0.070 |
Why?
|
Muscle Strength | 1 | 2007 | 136 | 0.070 |
Why?
|
Spatial Behavior | 1 | 2006 | 9 | 0.070 |
Why?
|
Enzyme Activation | 2 | 2021 | 120 | 0.070 |
Why?
|
Leg | 1 | 2006 | 52 | 0.060 |
Why?
|
Visual Acuity | 1 | 2006 | 39 | 0.060 |
Why?
|
Cell Count | 1 | 2005 | 79 | 0.060 |
Why?
|
Causality | 2 | 2020 | 56 | 0.060 |
Why?
|
alpha-Synuclein | 2 | 2018 | 132 | 0.060 |
Why?
|
Heart Failure | 1 | 2007 | 179 | 0.060 |
Why?
|
DNA-Binding Proteins | 2 | 2018 | 274 | 0.060 |
Why?
|
Muscle Rigidity | 1 | 2004 | 21 | 0.060 |
Why?
|
Hypokinesia | 1 | 2004 | 23 | 0.060 |
Why?
|
Genetic Predisposition to Disease | 1 | 2006 | 390 | 0.060 |
Why?
|
Alleles | 2 | 2015 | 221 | 0.050 |
Why?
|
Cytosine | 1 | 2023 | 5 | 0.050 |
Why?
|
Point Mutation | 1 | 2003 | 27 | 0.050 |
Why?
|
Tremor | 1 | 2004 | 117 | 0.050 |
Why?
|
Eicosapentaenoic Acid | 1 | 2022 | 9 | 0.050 |
Why?
|
Arachidonate 5-Lipoxygenase | 1 | 2022 | 6 | 0.050 |
Why?
|
Epoxide Hydrolases | 1 | 2022 | 11 | 0.050 |
Why?
|
Odds Ratio | 2 | 2017 | 268 | 0.050 |
Why?
|
Carnitine | 1 | 2022 | 8 | 0.050 |
Why?
|
Chromatography, Liquid | 1 | 2022 | 23 | 0.050 |
Why?
|
Tandem Mass Spectrometry | 1 | 2022 | 21 | 0.050 |
Why?
|
Kidney Function Tests | 1 | 2002 | 22 | 0.050 |
Why?
|
Fatty Acids | 1 | 2022 | 41 | 0.050 |
Why?
|
Hypoxia | 1 | 2022 | 36 | 0.050 |
Why?
|
Socioeconomic Factors | 2 | 2018 | 308 | 0.050 |
Why?
|
Reference Values | 1 | 2002 | 194 | 0.050 |
Why?
|
Databases, Factual | 1 | 2023 | 358 | 0.050 |
Why?
|
Tomography, Emission-Computed | 1 | 2001 | 9 | 0.050 |
Why?
|
Aphasia, Primary Progressive | 1 | 2001 | 2 | 0.050 |
Why?
|
Spinocerebellar Degenerations | 1 | 2001 | 4 | 0.050 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2021 | 36 | 0.050 |
Why?
|
Fatal Outcome | 1 | 2001 | 57 | 0.050 |
Why?
|
Arteriosclerosis | 1 | 2021 | 13 | 0.050 |
Why?
|
Inflammasomes | 1 | 2021 | 17 | 0.050 |
Why?
|
Stroke | 1 | 2004 | 274 | 0.050 |
Why?
|
NF-kappa B | 1 | 2021 | 118 | 0.040 |
Why?
|
Genotype | 2 | 2015 | 359 | 0.040 |
Why?
|
AIDS Dementia Complex | 1 | 2000 | 40 | 0.040 |
Why?
|
Life Style | 1 | 2020 | 201 | 0.040 |
Why?
|
National Institute on Aging (U.S.) | 1 | 2019 | 17 | 0.040 |
Why?
|
Self Report | 1 | 2020 | 221 | 0.040 |
Why?
|
Obesity | 1 | 2021 | 321 | 0.040 |
Why?
|
Blood-Brain Barrier | 1 | 2019 | 39 | 0.040 |
Why?
|
Polymorphism, Restriction Fragment Length | 1 | 1998 | 7 | 0.040 |
Why?
|
DNA Fingerprinting | 1 | 1998 | 6 | 0.040 |
Why?
|
Antitubercular Agents | 1 | 1998 | 12 | 0.040 |
Why?
|
Meningitis | 1 | 1998 | 8 | 0.040 |
Why?
|
Analysis of Variance | 2 | 2014 | 269 | 0.040 |
Why?
|
Species Specificity | 1 | 1998 | 42 | 0.040 |
Why?
|
Chi-Square Distribution | 1 | 2018 | 146 | 0.040 |
Why?
|
Canada | 1 | 1998 | 51 | 0.040 |
Why?
|
Prognosis | 1 | 2020 | 825 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2001 | 730 | 0.030 |
Why?
|
Likelihood Functions | 1 | 2017 | 27 | 0.030 |
Why?
|
Brazil | 1 | 2017 | 39 | 0.030 |
Why?
|
Exercise | 1 | 2020 | 473 | 0.030 |
Why?
|
Neurologic Examination | 2 | 2007 | 114 | 0.030 |
Why?
|
Arterial Pressure | 1 | 2016 | 12 | 0.030 |
Why?
|
Multivariate Analysis | 1 | 2017 | 331 | 0.030 |
Why?
|
Diagnosis | 1 | 2015 | 24 | 0.030 |
Why?
|
Educational Status | 1 | 2017 | 298 | 0.030 |
Why?
|
Genetic Association Studies | 1 | 2015 | 85 | 0.030 |
Why?
|
Healthy Volunteers | 1 | 2015 | 41 | 0.030 |
Why?
|
Actigraphy | 1 | 2015 | 99 | 0.030 |
Why?
|
Diet, High-Fat | 1 | 2014 | 16 | 0.030 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2015 | 324 | 0.030 |
Why?
|
Green Fluorescent Proteins | 1 | 2014 | 23 | 0.030 |
Why?
|
Animals, Newborn | 1 | 2014 | 45 | 0.030 |
Why?
|
Glycoproteins | 1 | 2014 | 46 | 0.030 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2013 | 41 | 0.030 |
Why?
|
Case-Control Studies | 1 | 2015 | 593 | 0.030 |
Why?
|
Delusions | 1 | 2012 | 10 | 0.030 |
Why?
|
Mice, Inbred C57BL | 1 | 2014 | 435 | 0.030 |
Why?
|
TDP-43 Proteinopathies | 1 | 2014 | 110 | 0.030 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2013 | 169 | 0.030 |
Why?
|
Age of Onset | 1 | 2012 | 99 | 0.030 |
Why?
|
Epidemiologic Studies | 1 | 2012 | 24 | 0.030 |
Why?
|
Phosphoserine | 1 | 2012 | 5 | 0.020 |
Why?
|
Cerebellar Cortex | 1 | 2012 | 7 | 0.020 |
Why?
|
Time Factors | 1 | 2016 | 1490 | 0.020 |
Why?
|
Drug Resistance | 1 | 2012 | 47 | 0.020 |
Why?
|
Rats | 1 | 2014 | 678 | 0.020 |
Why?
|
Glucose | 1 | 2012 | 55 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 2012 | 213 | 0.020 |
Why?
|
Treatment Outcome | 1 | 2020 | 3615 | 0.020 |
Why?
|
Gas Chromatography-Mass Spectrometry | 1 | 2009 | 13 | 0.020 |
Why?
|
Neocortex | 1 | 2009 | 31 | 0.020 |
Why?
|
Models, Neurological | 1 | 2009 | 25 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 97 | 0.020 |
Why?
|
Cholesterol | 1 | 2009 | 64 | 0.020 |
Why?
|
Up-Regulation | 1 | 2009 | 177 | 0.020 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2007 | 29 | 0.020 |
Why?
|
Long-Term Care | 1 | 2007 | 58 | 0.020 |
Why?
|
Florida | 1 | 2006 | 22 | 0.020 |
Why?
|
Pedigree | 1 | 2006 | 67 | 0.020 |
Why?
|
Ambulatory Care Facilities | 1 | 2006 | 40 | 0.020 |
Why?
|
Bias | 1 | 2006 | 41 | 0.020 |
Why?
|
Community Health Services | 1 | 2006 | 35 | 0.020 |
Why?
|
Mobility Limitation | 1 | 2006 | 94 | 0.020 |
Why?
|
Brain Chemistry | 1 | 2005 | 44 | 0.020 |
Why?
|
Syndrome | 1 | 2005 | 82 | 0.020 |
Why?
|
Gene Expression Regulation | 1 | 2007 | 281 | 0.020 |
Why?
|
Disability Evaluation | 1 | 2007 | 289 | 0.020 |
Why?
|
Practice Patterns, Physicians' | 1 | 2006 | 122 | 0.020 |
Why?
|
Observer Variation | 1 | 2005 | 102 | 0.020 |
Why?
|
Family | 1 | 2006 | 115 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2006 | 492 | 0.020 |
Why?
|
Antihypertensive Agents | 1 | 2005 | 81 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2006 | 517 | 0.010 |
Why?
|
Prevalence | 1 | 2006 | 467 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2005 | 352 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2006 | 320 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2006 | 733 | 0.010 |
Why?
|
Activities of Daily Living | 1 | 2007 | 608 | 0.010 |
Why?
|
Retrospective Studies | 1 | 2005 | 3609 | 0.010 |
Why?
|